Выбор редакции

Oramed Pharmaceutical begins recruiting patients for its ORMD-0801 study

  • Oramed (ORMP +0.1%) says it has initiated patient recruitment for a new clinical trial of its orally ingestible insulin capsule, ORMD-0801 for patients with type 1 diabetes mellitus in Israel.
  • The FDA cleared ORMD-0801 as an Investigational New Drug Application in May, as well as a grant from the Israeli government for further clinical development.
Post your comment!